Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen.
Braal CL, Hussaarts KGAM, Seuren L, Oomen-de Hoop E, de Bruijn P, Buck SAJ, Bos MEMM, Thijs-Visser MF, Zuetenhorst HJM, Mathijssen-van Stein D, Vastbinder MB, van Leeuwen RWF, van Gelder T, Koolen SLW, Jager A, Mathijssen RHJ. Braal CL, et al. Among authors: bos memm. Breast Cancer Res Treat. 2020 Nov;184(1):107-113. doi: 10.1007/s10549-020-05829-6. Epub 2020 Aug 16. Breast Cancer Res Treat. 2020. PMID: 32803636 Free PMC article. Clinical Trial.
Correction to: Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen.
Braal CL, Hussaarts KGAM, Seuren L, Oomen-deHoop E, de Bruijn P, Buck SAJ, Bos MEMM, Thijs-Visser MF, Zuetenhorst HJM, Mathijssen-van Stein D, Vastbinder MB, van Leeuwen RWF, van Gelder T, Koolen SLW, Jager A, Mathijssen RHJ. Braal CL, et al. Among authors: bos memm. Breast Cancer Res Treat. 2021 Feb;185(3):889. doi: 10.1007/s10549-020-05979-7. Breast Cancer Res Treat. 2021. PMID: 33226493 Free PMC article. No abstract available.
Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue.
de Jonge MM, Ruano D, van Eijk R, van der Stoep N, Nielsen M, Wijnen JT, Ter Haar NT, Baalbergen A, Bos MEMM, Kagie MJ, Vreeswijk MPG, Gaarenstroom KN, Kroep JR, Smit VTHBM, Bosse T, van Wezel T, van Asperen CJ. de Jonge MM, et al. Among authors: bos memm. J Mol Diagn. 2018 Sep;20(5):600-611. doi: 10.1016/j.jmoldx.2018.05.005. Epub 2018 Jun 21. J Mol Diagn. 2018. PMID: 29936257 Free article.
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
Claessens AKM, Bos MEMM, Lopez-Yurda M, Bouma JM, Rademaker-Lakhai JM, Honkoop AH, de Graaf H, van Druten E, van Warmerdam LJC, van der Sangen MJC, Tjan-Heijnen VCG, Erdkamp FLG; Dutch Breast Cancer Research Group (BOOG). Claessens AKM, et al. Among authors: bos memm. Breast Cancer Res Treat. 2018 Nov;172(2):413-423. doi: 10.1007/s10549-018-4906-8. Epub 2018 Aug 18. Breast Cancer Res Treat. 2018. PMID: 30121808 Clinical Trial.
The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer.
Claessens AKM, Timman R, Busschbach JJ, Bouma JM, Rademaker-Lakhai JM, Erdkamp FLG, Tjan-Heijnen VCG, Bos MEMM; Dutch Breast Cancer Research Group (BOOG). Claessens AKM, et al. Among authors: bos memm. Breast Cancer Res Treat. 2020 Feb;179(3):677-685. doi: 10.1007/s10549-019-05495-3. Epub 2019 Nov 28. Breast Cancer Res Treat. 2020. PMID: 31782032 Free PMC article.
Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study.
Eijkelboom AH, de Munck L, Vrancken Peeters MTFD, Broeders MJM, Strobbe LJA, Bos MEMM, Schmidt MK, Guerrero Paez C, Smidt ML, Bessems M, Verloop J, Linn S, Lobbes MBI, Honkoop AH, van den Bongard DHJG, Westenend PJ, Wesseling J, Menke-van der Houven van Oordt CW, Tjan-Heijnen VCG, Siesling S; NABON COVID-19 Consortium and the COVID and Cancer-NL Consortium. Eijkelboom AH, et al. Among authors: bos memm. J Hematol Oncol. 2021 Apr 17;14(1):64. doi: 10.1186/s13045-021-01073-7. J Hematol Oncol. 2021. PMID: 33865430 Free PMC article.
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.
Kester L, Seinstra D, van Rossum AGJ, Vennin C, Hoogstraat M, van der Velden D, Opdam M, van Werkhoven E, Hahn K, Nederlof I, Lips EH, Mandjes IAM, van Leeuwen-Stok AE, Canisius S, van Tinteren H, Imholz ALT, Portielje JEA, Bos MEMM, Bakker SD, Rutgers EJ, Horlings HM, Wesseling J, Voest EE, Wessels LFA, Kok M, Oosterkamp HM, van Oudenaarden A, Linn SC, van Rheenen J. Kester L, et al. Among authors: bos memm. Clin Cancer Res. 2022 Mar 1;28(5):960-971. doi: 10.1158/1078-0432.CCR-21-1442. Clin Cancer Res. 2022. PMID: 34965952 Free PMC article.
33 results